Here we discuss the potential of targeting Dihydroorotate dehydrogenase enzyme to help treat Covid 19. Next, we present a very large scale of docking analysis using 7900 drug candidates and 20 Dihydroorotate dehydrogenase structures. Our findings not only identify 28-FDA approved candidate molecules, but also show common characteristics among the candidates, especially their association with serotonin-dopamine receptors. In continuation, we discuss the existing clinical trials for Covid 19 treatment of some of the drug candidates we have identified, supporting that the rest are good candidates.

中文翻译：

---

Covid19治疗的综合药物再利用研究：新型推定的DHODH抑制剂显示与血清素多巴胺受体相关

在这里，我们讨论了靶向二氢乳清酸脱氢酶以帮助治疗Covid 19的潜力。接下来，我们介绍了使用7900种候选药物和20种二氢乳清酸脱氢酶结构的超大型对接分析。我们的发现不仅确定了28-FDA批准的候选分子，而且还显示出候选对象之间的共同特征，尤其是它们与5-羟色胺-多巴胺受体的关联。接下来，我们讨论了我们已经确定的一些候选药物用于Covid 19治疗的现有临床试验，并支持其余药物是好的候选药物。